EMEA-003299-PIP01-22 - paediatric investigation plan
Orforglipron
PIPHuman
Key facts
- Active Substance
- Orforglipron
- Therapeutic area
- Endocrine disorders
- Decision number
- P/0178/2024
- PIP number
- EMEA-003299-PIP01-22
- Pharmaceutical form(s)
- Capsule, hard
- Condition(s) / indication(s)
- Treatment of type 2 diabetes mellitus
- Route(s) of administration
- Oral use
- Contact for public enquiries
Eli Lilly and Company Ltd
E-mail: eu_paediatric@lilly.com
Phone: +44 1256315000- Decision type
- P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
- Decision date